타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 4개 · 임상 갱신 필요 4개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | ||||
|---|---|---|---|---|
Overview Program | Columvi (glofitamab) | Epkinly (epcoritamab) | Rituxan (rituximab) | Obinutuzumab |
Overview Company | Roche / Genentech | Genmab / AbbVie | Roche / Genentech | Roche / Genentech |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | CD20 × CD3 | CD20 × CD3 | CD20 | B-cell Lymphoma |
Overview Indication | Relapsed or refractory diffuse large B-cell lymphoma | Relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma | US label: non-Hodgkin lymphoma, CLL, rheumatoid arthritis, GPA/MPA and pemphigus vulgaris; population-specific indications | Breast Adenocarcinoma; Metastatic Breast Carcinoma |
Overview Phase | APPROVED | APPROVED | APPROVED | PHASE_3 |
Overview Status | APPROVED | APPROVED | APPROVED | RECRUITING |
Overview Content status | Curated Core | Curated Core | Curated Core | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Emerging |
Overview Approval status | FDA approved | FDA approved | FDA approved | Investigational |
Positioning Key differentiator | Bivalent CD20 binding increases avidity; obinutuzumab pretreatment debulks circulating B cells to blunt first-dose CRS. | Subcutaneous dosing gives slower Cmax and lower grade ≥3 CRS than IV engagers. | novel synthetic binding reagents to each of these mAbs | novel calcineurin inhibitor with predictable pharmacokinetics, increases complete renal response rates and rapidly reduces pr |
Positioning Known limitation | CD20 loss after prior anti-CD20 therapy and T-cell exhaustion. | CD20 antigen loss and exhausted effector T cells after multiple prior lines. | bypassing agents | resistance to treatment |
Positioning Development positioning | 3L+ | 3L+ | — | — |
MoA Mechanism | Crosslinks CD20 on malignant B cells with CD3 on T cells; the 2:1 geometry stabilizes the synapse and drives T-cell activation and B-cell lysis. | Bispecific binding of CD20 on B cells and CD3 on T cells creates a cytolytic synapse; the silenced Fc prevents Fcγ-receptor-driven off-target activation. | target cells via receptor | targets type I interferon signaling |
MoA Biomarker | CD20 expression; ctDNA clearance investigational. | CD20 expression; ctDNA MRD investigational. | CD20 mAbs: rituximab; ofatumumab; and obinutuzumab, were screened in high | biomarker to guide treatment duration in two prospective trials of venetoclax- and sonrotoclax-based triplets |
Toxicology Major finding | Boxed warning for CRS. Neurologic events, infection, neutropenia, and tumor flare require monitoring. | Boxed warning for CRS and ICANS. Injection-site reactions, neutropenia, and infection are common. | — | — |
Toxicology CRS | CRS ~63%, grade ≥3 ~4% | CRS ~50%, grade ≥3 ~2.5% | — | — |
Clinical Safety signal | Boxed warning for CRS. Neurologic events, infection, neutropenia, and tumor flare require monitoring. | Boxed warning for CRS and ICANS. Injection-site reactions, neutropenia, and infection are common. | — | — |
Clinical Program phase | APPROVED | APPROVED | APPROVED | PHASE_3 |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts | No active/completed counts |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 4개 · 임상 갱신 필요 4개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | ||||
|---|---|---|---|---|
Overview Program | Columvi (glofitamab) | Epkinly (epcoritamab) | Rituxan (rituximab) | Obinutuzumab |
Overview Company | Roche / Genentech | Genmab / AbbVie | Roche / Genentech | Roche / Genentech |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | CD20 × CD3 | CD20 × CD3 | CD20 | B-cell Lymphoma |
Overview Indication | Relapsed or refractory diffuse large B-cell lymphoma | Relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma | US label: non-Hodgkin lymphoma, CLL, rheumatoid arthritis, GPA/MPA and pemphigus vulgaris; population-specific indications | Breast Adenocarcinoma; Metastatic Breast Carcinoma |
Overview Phase | APPROVED | APPROVED | APPROVED | PHASE_3 |
Overview Status | APPROVED | APPROVED | APPROVED | RECRUITING |
Overview Content status | Curated Core | Curated Core | Curated Core | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Emerging |
Overview Approval status | FDA approved | FDA approved | FDA approved | Investigational |
Positioning Key differentiator | Bivalent CD20 binding increases avidity; obinutuzumab pretreatment debulks circulating B cells to blunt first-dose CRS. | Subcutaneous dosing gives slower Cmax and lower grade ≥3 CRS than IV engagers. | novel synthetic binding reagents to each of these mAbs | novel calcineurin inhibitor with predictable pharmacokinetics, increases complete renal response rates and rapidly reduces pr |
Positioning Known limitation | CD20 loss after prior anti-CD20 therapy and T-cell exhaustion. | CD20 antigen loss and exhausted effector T cells after multiple prior lines. | bypassing agents | resistance to treatment |
Positioning Development positioning | 3L+ | 3L+ | — | — |
MoA Mechanism | Crosslinks CD20 on malignant B cells with CD3 on T cells; the 2:1 geometry stabilizes the synapse and drives T-cell activation and B-cell lysis. | Bispecific binding of CD20 on B cells and CD3 on T cells creates a cytolytic synapse; the silenced Fc prevents Fcγ-receptor-driven off-target activation. | target cells via receptor | targets type I interferon signaling |
MoA Biomarker | CD20 expression; ctDNA clearance investigational. | CD20 expression; ctDNA MRD investigational. | CD20 mAbs: rituximab; ofatumumab; and obinutuzumab, were screened in high | biomarker to guide treatment duration in two prospective trials of venetoclax- and sonrotoclax-based triplets |
Toxicology Major finding | Boxed warning for CRS. Neurologic events, infection, neutropenia, and tumor flare require monitoring. | Boxed warning for CRS and ICANS. Injection-site reactions, neutropenia, and infection are common. | — | — |
Toxicology CRS | CRS ~63%, grade ≥3 ~4% | CRS ~50%, grade ≥3 ~2.5% | — | — |
Clinical Safety signal | Boxed warning for CRS. Neurologic events, infection, neutropenia, and tumor flare require monitoring. | Boxed warning for CRS and ICANS. Injection-site reactions, neutropenia, and infection are common. | — | — |
Clinical Program phase | APPROVED | APPROVED | APPROVED | PHASE_3 |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts | No active/completed counts |
추천 비교
추천 비교